SoftServe Reviews Impact of 21st Century Cures Act on Pharmaceutical Sector

SoftServe healthcare expert predicts more collaboration between technology and biopharmaceutical industries

Nov 02, 2015, 09:10 ET from SoftServe

AUSTIN, Texas, Nov. 2, 2015 /PRNewswire/ -- On July 10, 2015, the 21st Century Cures Act (H.R. 6) went before the US Senate for approval and implementation. The bill will speed up the approval process for drugs and healthcare devices, and spur biomedical innovation. If passed it will significantly affect pharmaceutical research and healthcare. The bill also mentions utilization of the Precision Medicine program, an emerging approach for disease treatment and provision which takes into account differences in patients' genes, environment, and lifestyle.

In a new whitepaper SoftServe's healthcare expert, Eugene Borukhovich, reviews 5 possible scenarios for the pharmaceutical sector after the inclusion of much more technology-driven healthcare innovation and the introduction of additional personal data and information into health science:

1.       Increased use of biomarkers for precision medicine drugs
2.       Even more R&D investment into personalized medicine
3.       More collaboration between the digital technology industry and the biopharma sector
4.       More health initiatives with the word "precision" in the title
5.       Drug development for children with rare diseases

"While the healthcare industry is still figuring out population health management, the 21st Century Cures Act, if passed, will help significantly accelerate the drug and device development process in order to provide more personalized and targeted treatments for individual healthcare consumers. The Pharmaceutical industry is no longer all about compounds, the bits and bytes of consumer's behaviors, their vital signs and activities during clinical trials and in the 'wild', will all help shape an outcomes based culture." said Eugene Borukhovich, Senior Vice President and Global Vertical Practice Leader, Healthcare.

Learn more about the emergence of new technologies related to this Act in SoftServe's whitepaper "Precision medicine and the 21st century Cures Act: 5 scenarios on the Future of the Pharmaceutical Sector".

About SoftServe

SoftServe ( is a leading technology solutions company specializing in software development and consultancy services. Since 1993 we've been partnering with organizations from start-ups to large enterprises to help them accelerate growth and innovation, transform operational efficiency, and deliver new products to market.

Our experience stretches from Big Data/Analytics, Cloud, Security and UX Design to the Internet of Things, Digital Health and Digital Transformation, we have offices across the globe and development centers across Eastern Europe.

Nataliya Diomova
US: 866-687-3588 x1282 


SOURCE SoftServe